Patient‐reported pain intensity or pain relief (VAS, NRS or categorical scale) · patients with LBP
1 finding from 1 review
Function (higher scores mean more disability) ‐ Short‐term · patients with LBP
1 finding from 1 review
Function (higher scores mean more disability) ‐ Long‐term · patients with LBP
1 finding from 1 review
Adverse events Self‐reported · patients with LBP
1 finding from 1 review
Pain intensity various scales short‐term · patients with LBP
1 finding from 1 review
Patient‐reported pain intensity or pain relief (VAS, NRS or categorical scale) · patients with LBP
1 finding from 1 review
Function (higher scores mean more disability) ‐ Short‐term · patients with LBP
1 finding from 1 review
Function (higher scores mean more disability) ‐ Long‐term · patients with LBP
1 finding from 1 review
Remission of anxiety diagnoses (ITT analysis) i.e. no longer meeting criteria for DSM or ICD anxiety diagnosis at the end of the trial. · children and adolescents with anxiety disorders
CBT showed no clear difference in remission of anxiety diagnoses (ITT) analysis i.e. no longer meeting… compared with active controls (moderate certainty).
1 finding from 1 review
Reduction in anxiety symptoms (parent report) post‐treatment · children and adolescents with anxiety disorders
1 finding from 1 review
Remission (combined clinical and endoscopic remission) · Adult patients with active ulcerative colitis
Budesonide MMX® 9 mg probably leads to higher remission (combined clinical and endoscopic remission) compared with placebo (moderate certainty).
1 finding from 1 review
Endoscopic improvement (dichotomous) · Adult patients with active ulcerative colitis
Budesonide MMX® 6 mg showed no clear difference in endoscopic improvement compared with placebo (moderate certainty).
1 finding from 1 review
Histologic remission · Adult patients with active ulcerative colitis
Budesonide MMX® 6 mg showed no clear difference in histologic remission compared with placebo (low certainty).
1 finding from 1 review
Serious adverse events · Adult patients with active ulcerative colitis
Budesonide MMX® 6 mg showed no clear difference in serious adverse events compared with placebo (low certainty).
1 finding from 1 review
Adverse events · Adult patients with active ulcerative colitis
It is very uncertain whether budesonide MMX® 6 mg changes adverse events compared with placebo (very low certainty).
1 finding from 1 review
Withdrawals due to adverse events · Adult patients with active ulcerative colitis
Budesonide MMX® 6 mg showed no clear difference in withdrawal due to adverse events compared with placebo (low certainty).
1 finding from 1 review
Endoscopic improvement (dichotomous) · Adult patients with active ulcerative colitis
Budesonide 10 mg showed no clear difference in endoscopic improvement compared with prednisolone 40 mg (low certainty).
1 finding from 1 review
Endoscopic remission · Adult patients with active ulcerative colitis
It is very uncertain whether budesonide 10 mg changes endoscopic remission compared with prednisolone 40 mg (very low certainty).
1 finding from 1 review
Histologic remission · Adult patients with active ulcerative colitis
It is very uncertain whether budesonide 10 mg changes histologic remission compared with prednisolone 40 mg (very low certainty).
1 finding from 1 review
Adverse event ‐ Reduction in plasma cortisol below lower reference limit · Adult patients with active ulcerative colitis
It is very uncertain whether budesonide 10 mg changes adverse event ‐ Reduction in plasma cortisol below lower reference… compared with prednisolone 40 mg (very low certainty).
1 finding from 1 review